Literature DB >> 21901397

The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia.

Filip Razga1, Zdenek Racil2, Katerina Machova Polakova3, Lucie Buresova4, Hana Klamova3, Daniela Zackova1, Dana Dvorakova1, Vaclava Polivkova3, Petr Cetkovsky3, Jiri Mayer1,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21901397     DOI： 10.1007/s12185-011-0924-6

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  10 in total

1.  hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia.

Authors:  A Bazeos; D Marin; A G Reid; G Gerrard; D Milojkovic; P C May; H de Lavallade; P Garland; K Rezvani; J F Apperley; J M Goldman; L Foroni; J S Khorashad
Journal:  Leukemia       Date:  2010-05-06       Impact factor: 11.528

2.  OCT-1 function varies with cell lineage but is not influenced by BCR-ABL.

Authors:  Jane R Engler; Andrew C W Zannettino; Charles G Bailey; John E J Rasko; Timothy P Hughes; Deborah L White
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

3.  Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib.

Authors:  Deborah L White; Phuong Dang; Jane Engler; Amity Frede; Stephanie Zrim; Michael Osborn; Verity A Saunders; Paul W Manley; Timothy P Hughes
Journal:  J Clin Oncol       Date:  2010-04-26       Impact factor: 44.544

4.  Assessment of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) mRNA expression in patients with de novo chronic myelogenous leukemia: the role of different cell types.

Authors:  Zdenek Racil; Filip Razga; Katerina Machova Polakova; Lucie Buresova; Vaclava Polivkova; Dana Dvorakova; Daniela Zackova; Hana Klamova; Petr Cetkovsky; Jiri Mayer
Journal:  Leuk Lymphoma       Date:  2010-12-06

5.  Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity.

Authors:  Deborah L White; Verity A Saunders; Phuong Dang; Jane Engler; Amity Venables; Stephanie Zrim; Andrew Zannettino; Kevin Lynch; Paul W Manley; Timothy Hughes
Journal:  Blood       Date:  2007-08-30       Impact factor: 22.113

6.  Active transport of imatinib into and out of cells: implications for drug resistance.

Authors:  Julia Thomas; Lihui Wang; Richard E Clark; Munir Pirmohamed
Journal:  Blood       Date:  2004-08-17       Impact factor: 22.113

7.  Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia.

Authors:  L Wang; A Giannoudis; S Lane; P Williamson; M Pirmohamed; R E Clark
Journal:  Clin Pharmacol Ther       Date:  2007-06-13       Impact factor: 6.875

8.  Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells.

Authors:  Chie Hirayama; Hiroshi Watanabe; Reiko Nakashima; Takeru Nanbu; Akinobu Hamada; Akihiko Kuniyasu; Hitoshi Nakayama; Tatsuya Kawaguchi; Hideyuki Saito
Journal:  Pharm Res       Date:  2007-10-13       Impact factor: 4.200

Review 9.  Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.

Authors:  Michele Baccarani; Jorge Cortes; Fabrizio Pane; Dietger Niederwieser; Giuseppe Saglio; Jane Apperley; Francisco Cervantes; Michael Deininger; Alois Gratwohl; François Guilhot; Andreas Hochhaus; Mary Horowitz; Timothy Hughes; Hagop Kantarjian; Richard Larson; Jerald Radich; Bengt Simonsson; Richard T Silver; John Goldman; Rudiger Hehlmann
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

10.  The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population.

Authors:  Zdenek Racil; Filip Razga; Lucie Buresova; Tomas Jurcek; Dana Dvorakova; Daniela Zackova; Shira Timilsina; Petr Cetkovsky; Jiri Mayer
Journal:  Am J Hematol       Date:  2010-07       Impact factor: 10.047
  10 in total
  5 in total

Review 1.  Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics?

Authors:  V Némethová; F Rázga
Journal:  Leukemia       Date:  2016-10-21       Impact factor: 11.528

2.  Significance of OCT1 Expression in Acute Myeloid Leukemia.

Authors:  Ewa Stefanko; Justyna Rybka; Bożena Jaźwiec; Olga Haus; Sylwia Stąpor; Kazimierz Kuliczkowski; Tomasz Wróbel
Journal:  Pathol Oncol Res       Date:  2016-12-26       Impact factor: 3.201

3.  OCT-1 Expression in Patients with Chronic Myeloid Leukemia: A Comparative Analysis with Respect to Response to Imatinib Treatment.

Authors:  Betul Bozkurt Bulakcı; Aynur Daglar Aday; Basak Gurtekin; Akif Selim Yavuz; Sukru Ozturk; Kivanc Cefle; Ayse Palanduz; Sukru Palanduz
Journal:  Indian J Hematol Blood Transfus       Date:  2022-04-11       Impact factor: 0.915

Review 4.  Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia.

Authors:  Raquel C Maia; Flavia C Vasconcelos; Paloma S Souza; Vivian M Rumjanek
Journal:  Molecules       Date:  2018-01-07       Impact factor: 4.411

5.  ABCB1 and BMI1 mRNA expression in patients with chronic myeloid leukemia: impact on imatinib efficacy.

Authors:  Ahmed M L Bedewy; Shereen M Elmaghraby; Noha S Kandil
Journal:  Blood Res       Date:  2019-03-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.